A Form 4 filed on August 19, 2026, discloses that Shane Bohnen, SVP and General Counsel of BIO-TECHNE Corp (NASDAQ:TECH), acquired two tranches of Restricted Stock Units on August 17, 2026, with no shares of common stock reported in Table I following the transactions.

Key Highlights

  • RSU Grant 1: Bohnen acquired 11,344 Restricted Stock Units on August 17, 2026, at a price of $0, vesting in three installments: 3,781 units on each of August 17, 2027 and August 17, 2028, and 3,782 units on August 17, 2029.
  • RSU Grant 2: Bohnen acquired 18,432 Restricted Stock Units on August 17, 2026, at a price of $0, with all 18,432 units vesting on August 17, 2029.
  • Common Stock Ownership: Table I lists 10,360 shares of Common Stock directly owned, with no transaction code or price recorded for that position.
  • Existing Options: Bohnen holds stock options covering a combined 68,334 shares of Common Stock across eight separate grants, with exercise prices ranging from $53.60 to $120.46.
  • Performance RSUs: Bohnen also holds Performance Restricted Stock Units covering 13,992 and 10,012 shares, each vesting in full or in part upon achievement of certain performance goals, as described in the filing.
  • Reporting Role: Bohnen is identified as an officer with the title SVP - General Counsel; the form was signed by Andrew Nick as Attorney-in-Fact pursuant to a previously filed Power of Attorney.

Bio-Techne General Counsel's August 2026 Equity Award Details

According to the filing, Shane Bohnen, serving as SVP and General Counsel of BIO-TECHNE Corp, received two grants of Restricted Stock Units on August 17, 2026. The first grant consists of 11,344 units that vest across three dates: 3,781 units on August 17, 2027, 3,781 units on August 17, 2028, and 3,782 units on August 17, 2029. The second grant consists of 18,432 units, all vesting on August 17, 2029. Both grants were acquired at a stated price of $0. The filing notes that each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

The filing also reports that Bohnen holds eight separate stock option grants covering Common Stock, with exercise prices of $66.97, $120.46, $94.52, $73.76, $84.61 (two separate grants of 807 and 16,302 shares), $74.91, and $53.60, according to the filing. Several of these options are described as fully exercisable, while others remain on vesting schedules extending through August 2028. In addition, Bohnen holds two Performance Restricted Stock Unit positions covering 13,992 and 10,012 shares of Common Stock, each subject to vesting contingent on achievement of certain performance goals on August 15, 2027 and August 15, 2028, respectively, or such later date as performance is certified by the Administrator, as stated in the filing.

Table I of the filing lists 10,360 shares of Common Stock as directly owned by Bohnen following the reported transactions, though no transaction code or per-share price is recorded for that row in the source document.

What Was Disclosed

The filing discloses two Restricted Stock Unit grants totaling 29,776 units awarded to BIO-TECHNE Corp's SVP and General Counsel Shane Bohnen on August 17, 2026, along with his existing holdings of stock options and Performance Restricted Stock Units as of the filing date.